Key Investor Signals
$19.75M in signed LOIs from 11 clinics
Adialante reports $19.75M in total contract value from signed letters of intent across 11 clinics, up from $12.75M and 6 clinics at its April 2026 YC launch.
Holds two issued US patents covering its core compact MRI methods.
CEO Efraín Torres and University of Minnesota MRI physicist Michael Garwood are co-inventors on two issued U.S. patents covering frequency-modulated RF gradient methods for MRI.
Selected for Y Combinator Spring 2026
Adialante was selecterd to join 's Spring 2026 batch.
Other Positive Signals
- Won a $1.18M NSF grant, bringing total non-dilutive funding above $3M.
- Member of the medtech-focused incubator since 2024.
- Founders have published MRI research in Magnetic Resonance in Medicine and IEEE Transactions on Medical Imaging.
Team
Dr. Efraín Torres
CEO & Co-Founder
- Earned a PhD in biomedical engineering from the University of Minnesota in 2023 after completing a biomedical engineering degree at Marquette University.
- Conducted MRI research at the University of Minnesota's Center for Magnetic Resonance Research under MRI physicist Michael Garwood.
- First-authored the foundational Magnetic Resonance in Medicine paper introducing frequency-modulated Rabi-encoded echoes for MRI without conventional gradient encoding.
- Named co-inventor on two issued U.S. patents covering frequency-modulated RF spatial encoding for MRI.
Parker Jenkins
COO & Co-Founder
- Pursuing a PhD in biomedical engineering at the University of Minnesota, with research focused on radiofrequency encoding methods for lower-cost MRI.
- Conducted MRI research at the University of Minnesota's Center for Magnetic Resonance Research under Michael Garwood.
- Co-authored peer-reviewed research in Magnetic Resonance in Medicine on correcting image distortions in frequency-modulated Rabi-encoded MRI.
- Won the student division and grand prize at the University of Minnesota's December 2023 Walleye Tank pitch competition, and completed the national commercialization program with the Adialante team.
Product
Adialante is developing a compact mobile MRI system for use at urology clinics. Its first application is prostate imaging before biopsy. The company plans to own and operate the mobile units, charging clinics a flat fee for each scan.
Initial clinical application
Adialante is starting with men who require MRI before a prostate biopsy. This provides the company with a focused entry point in a guideline-supported but underused diagnostic workflow.
Compact MRI architecture
Adialante's gradient-free design uses 50% less hardware and requires no liquid helium. The company states that its scanner is approximately 40% shorter, 80% lighter, and uses 60% less power than a conventional system. It requires neither a shielded room nor specialised infrastructure.
Mobile, per-scan delivery
Adialante plans to own and operate each mobile unit rather than sell scanners to clinics. Clinics pay a flat fee per scan, avoiding the capital cost of purchasing a system while retaining the associated insurance reimbursement.
Market Overview
Clinical guidelines increasingly recommend MRI before prostate biopsy because it can improve the detection of clinically significant cancers and reduce unnecessary procedures. Adoption remains limited: only 35.5% of US prostate biopsies were preceded by an MRI in 2022, with access lower in rural areas.
The main constraint is delivery. Most urology clinics cannot provide MRI in-house, requiring patients to visit a hospital or imaging centre. Mobile MRI services can bring imaging closer to these clinics without requiring them to purchase a conventional scanner or build specialised infrastructure.
Projected market growth from 2024 to 2030.
Share of US prostate biopsies preceded by an MRI in 2022, up from 0.5% in 2007.
Projected market growth from 2024 to 2030.
Difference in use between rural and urban areas in the United States.
Comparable Outcomes
Hyperfine
Hyperfine developed Swoop, the first FDA-cleared portable ultra-low-field MRI system designed to provide brain imaging at the point of care. Hyperfine and Liminal Sciences completed a business combination with HealthCor Catalio Acquisition Corp. in December 2021. The combined company had an approximately $580M enterprise value and listed on Nasdaq as HYPR.
Butterfly Network
Butterfly Network developed Butterfly iQ, a handheld ultrasound system using semiconductor technology to perform whole-body imaging through a single probe connected to a smartphone or tablet. Butterfly completed its merger with Longview Acquisition Corp. in February 2021 at a $1.5B pro forma enterprise value and began trading on the NYSE as BFLY.
Prenuvo
Prenuvo built a direct-to-consumer whole-body MRI screening service delivered through a network of dedicated imaging centers. The company generated approximately $100M in 2024 revenue and reached around 110,000 members, demonstrating commercial demand for MRI screening outside traditional hospital referral pathways.
Have a question about Adialante?
Ask DealBio. We may research the answer or share selected questions with the company.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.